Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Pharma
Enspryng falls short of Roche's expectations in myasthenia gravis
Roche’s labeling Enspryng’s data as weak was a relief for other developers of biologics for gMG, such as Johnson & Johnson, UCB and argenx.
Angus Liu
Mar 21, 2024 11:28am
Argenx's Vyvgart comes up short of placebo in ITP trial
Nov 28, 2023 11:20am
Subcutaneous Vyvgart helps Argenx treat a 'broader population'
Nov 1, 2023 9:35am
With Zilbrysq, UCB gains its second FDA nod in gMG in 4 months
Oct 18, 2023 1:08pm
FDA signs off on UCB's myasthenia gravis drug Rystiggo
Jun 27, 2023 11:28am
Argenx CEO confident company can achieve 'standalone' success
Sep 14, 2022 9:30am